1
|
Omoti AE and Omoti CE: Ocular toxicity of
systemic anticancer chemotherapy. Pharm Pract (Granada). 4:55–59.
2006. View Article : Google Scholar : PubMed/NCBI
|
2
|
Li Y, Li Y, Li J, Pi G and Tan W:
Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: A case
report and literature review. Onco Targets Ther. 7:1361–1366.
2014.PubMed/NCBI
|
3
|
Uterine Neoplasms: NCCN Guidelines Version
2 MS. 19:2016.
|
4
|
Berman IJ and Mann MP: Seizures and
transient cortical blindness associ-ated with cisplatinum (II)
diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer.
45:764–766. 1980. View Article : Google Scholar : PubMed/NCBI
|
5
|
Wilding G, Caruso R, Lawrence TS, Ostchega
Y, Ballintine EJ, Young RC and Ozols RF: Retinal toxicity after
high dose cisplatin therapy. J Clin Oncol. 3:1683–1689. 1985.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Kupersmith MJ, Seiple WH, Holopigian K,
Noble K, Hiesiger E and Warren F: Maculopathy caused by
intra-arterially administered cisplatin and intravenously
administered carmustine. Am J Ophthalmol. 113:435–438. 1992.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Khawly JA, Rubin P, Petros W, Peters WP
and Jaffe GJ: Retinopathy and optic neuropathy in bone marrow
transplantation for breast cancer. Ophthalmology. 103:87–95. 1996.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Hilliard LM, Berkow RL, Watterson J,
Ballard EA, Balzer GK and Moertel CL: Retinal toxicity associated
with cisplatin and etoposide in pediatric patients. Med Pediatr
Oncol. 28:310–313. 1997. View Article : Google Scholar : PubMed/NCBI
|
9
|
Tan WW and Walsh T: Ocular toxicity
secondary to paclitaxel in two lung cancer patients. Med Pediatr
Oncol. 31:1771998. View Article : Google Scholar : PubMed/NCBI
|
10
|
Wang MY, Arnold AC, Vinters HV and Glasgow
BJ: Bilateral blindness and lumbosacral myelopathy associated with
high-dose carmustine and cisplatin therapy. Am J Ophthalmol.
130:367–368. 2000. View Article : Google Scholar : PubMed/NCBI
|
11
|
Gonzalez F, Menendez D and Gomez-Ulla F:
Monocular visual loss in a patient undergoing cisplatin
chemotherapy. Int Ophthalmol. 24:301–304. 2001. View Article : Google Scholar : PubMed/NCBI
|
12
|
Watanabe W, Kuwabara R, Nakahara T,
Hamasaki O, Sakamoto I, Okada K, Minamoto A and Mishima HK: Severe
ocular and orbital toxicity after intracarotid injection of
carboplatin for recurrent glioblastomas. Graefes Arch Clin Exp
Ophthalmol. 240:1033–1035. 2002. View Article : Google Scholar : PubMed/NCBI
|
13
|
Katz BJ, Ward JH, Digre KB, Creel DJ and
Mamalis N: Persistent severe visual and electroretinographic
abnormalities after intravenous Cisplatin therapy. J
Neuroophthalmol. 23:132–135. 2003. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kwan AS, Sahu A and Palexes G: Retinal
ischemia with neovascularization in cisplatin related retinal
toxicity. Am J Ophthalmol. 141:196–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
15
|
Valeshabad A Kord, Mieler WF, Setlur V,
Thomas M and Shahidi M: Posterior segment toxicity after
gemcitabine and docetaxel chemotherapy. Optom Vis Sci.
92:e110–e113. 2015. View Article : Google Scholar : PubMed/NCBI
|
16
|
Togna GI, Togna AR, Franconi M and Caprino
L: Cisplatin triggers platelet activation. Thromb Res. 99:503–509.
2000. View Article : Google Scholar : PubMed/NCBI
|
17
|
Scaioli V, Caraceni A, Martini C, Curzi S,
Capri G and Luca G: Electrophysiological evaluation of visual
pathways in paclitaxel-treated patients. J Neurooncol. 77:79–87.
2006. View Article : Google Scholar : PubMed/NCBI
|
18
|
Bakbak B, Gedik S, Koktekir BE, Yavuzer K,
Tulek B, Kanat F and Pancar E: Assessment of ocular neurotoxicity
in patients treated with systemic cancer chemotherapeutics. Cutan
Ocul Toxicol. 33:7–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Walsh TJ, Clark AW, Parhad IM and Green
WR: Neurotoxic effects of cisplatin therapy. Arch Neurol.
39:719–720. 1982. View Article : Google Scholar : PubMed/NCBI
|
20
|
Hershman DL, Till C, Wright JD, Awad D,
Ramsey SD, Barlow WE, Minasian LM and Unger J: Comorbidities and
risk of chemotherapy-induced peripheral neuropathy among
participants 65 years or older in southwest oncology group clinical
trials. J Clin Oncol. 34:3014–3022. 2016. View Article : Google Scholar : PubMed/NCBI
|